Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM) (ONCOGRAM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03133273 |
Recruitment Status :
Active, not recruiting
First Posted : April 28, 2017
Last Update Posted : May 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Metastatic Chemotherapy | Other: Oncogramme® | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 256 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients corresponding to the inclusion criteria and having a histologically proven metastatic CRC on biopsies or primary tumor excision and / or one or more metastatic sites will be recruited prospectively and randomized into two groups.
For both groups, the adjuvant treatment will be decided in the multidisciplinary consultation meeting (MCM), according to the recommendations in force and adapted to the general medical condition of the patient. For patients in the Oncogramme group, chemotherapy will be adapted to Oncogramme. |
Masking: | Single (Participant) |
Masking Description: | The result of Oncogramme® will not give to the patient. |
Primary Purpose: | Other |
Official Title: | Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® |
Actual Study Start Date : | July 24, 2017 |
Estimated Primary Completion Date : | July 24, 2024 |
Estimated Study Completion Date : | July 24, 2024 |
Arm | Intervention/treatment |
---|---|
No Intervention: Usual care
Patient is followed within the usual care for stage 4 colorectal cancer
|
|
Experimental: Oncogramme®
For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
|
Other: Oncogramme®
Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results. |
- Occurrence of the progression or death of the patient. [ Time Frame: Year 1 ]The event studied is the occurrence of the progression or death of the patient during the year following the inclusion in the study. The progression of the patient is determined by the RECIST (Response Evaluation Criteria in Solid Tumors).
- Response to first-line treatment administrated [ Time Frame: every month, up to 12 months ]Percentage of patients in each response category to first-line treatment administered, evaluated by RECIST in each of the two groups.
- Overall survival [ Time Frame: Month 6 and Year 1 ]The event study is the death of the patient during the 6 months and the year following the inclusion.
- Specific survival [ Time Frame: Month 6 and Year 1 ]The event considered is death due to illness during the 6 months and the year following the inclusion. The attribution of the death to the illness will be made by the adjudication committee.
- Incremental Cost / Efficiency Ratio [ Time Frame: Year 1 ]Calculation of the Incremental Cost / Efficiency Ratio (ICER) expressed in euros per year of life gained without occurrence of death or progression to 1 year of the adapted chemotherapeutic treatment according to the results of Oncogramme® using EQ5D-5L s
- Incremental Cost / Utility Ratio [ Time Frame: Year 1 ]Calculation of the Incremental Cost / Utility Ratio (ICUR) expressed in euros per QALY gained at 1 year of the adapted chemotherapeutic treatment according to the results of Oncogramme® using EQ5D-5L scale.
- Quality of life [ Time Frame: Month 3, Month 6, Month 9 and Year 1 ]Compare the quality of life of patients at 3 months, 6 months, 9 months and 1 year between the two groups using the EQ5D-5L questionary score.
- No adaptation of chemotherapy [ Time Frame: every month, up to 12 months ]If there is no adaptation of the treatment to the results of Oncogramme®, describe the criteria that led to the failure to take into account the results of Oncogramme®
- Grade 3 and higher adverse events related to chemotherapy [ Time Frame: Year 1 ]Describe and compare in both groups the proportion of grade 3 and higher adverse events related to chemotherapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- Patient with metastatic colon or rectal adenocarcinoma (Stage IV) who can benefit from standard systemic chemotherapy (monotherapy based on 5-FU, polychemotherapy type FOLFOX, FOLFIRI, FOLFIRINOX, associated or not with targeted therapies Adapted to the expression of BRAF and RAS, whatever the route of administration of the proposed, oral or intravenous therapies)
- Metastatic CRC diagnosed preoperatively on imaging or per-operative on macroscopic findings and proved by histological analysis (biopsy or surgical excision and if possible biopsies or excrescence on the metastatic sites)
- Measurable metastases according to RECIST
- Chemotherapy for curative or palliative purposes
- Patient with consent.
- Affiliate or beneficiary of a social security scheme.
Exclusion Criteria:
- Formal contraindication to paraclinic exploration essential for patient follow-up
- Exclusive use of radiotherapy, targeted therapy, immunotherapy or hormone therapy, exclusive palliative support
- Patient with an absolute contraindication to the administration of chemotherapy
- Pregnant, lactating or non-contraceptive women for childbearing age women
- Patient with a difficulty of understanding the protocol
- Patient under protective measures (guardianship, curatorship, etc.).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03133273
France | |
CHU d'AMIENS | |
Amiens, France, 80054 | |
Bergonié Institut | |
Bordeaux, France, 33076 | |
Clinique des Cédres | |
Brive-la-Gaillarde, France, 19100 | |
CHU de TOURS | |
Chambray-lès-Tours, France, 37170 | |
Clermont-Ferrand University Hospital | |
Clermont-Ferrand, France, 63003 | |
CHu de la Martinique | |
Fort-De-France, France, 97261 | |
Hospital Center | |
Guéret, France, 23000 | |
Limoges University Hospital | |
Limoges, France, 87042 | |
Nimes University Hospital | |
Nîmes, France, 30029 | |
CHU de POITIERS | |
Poitiers, France, 86021 | |
CH de Saint Junien | |
Saint-Junien, France, 87200 | |
Centre Médical MGEN Alfred Leune | |
Sainte-Feyre, France, 23000 | |
CHU de Strasbourg | |
Strasbourg, France, 67000 |
Principal Investigator: | Muriel Mathonnet, MD | University Hospital, Limoges |
Responsible Party: | University Hospital, Limoges |
ClinicalTrials.gov Identifier: | NCT03133273 |
Other Study ID Numbers: |
I16014 (ONCOGRAM) |
First Posted: | April 28, 2017 Key Record Dates |
Last Update Posted: | May 25, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colorectal Cancer Metastatic Chemosensitivity |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |